Hepatitis C in Iran. How extensive of a problem is it?

Archives of Iranian Medicine

Volumn 15, Issue 5, 2012, Pages 268-

  Merat, Shahin ^a   Poustchi, Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B;

CHRONICITY; DISEASE SURVEILLANCE; EDITORIAL; ERADICATION THERAPY; ETHNIC GROUP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HELP SEEKING BEHAVIOR; HEMODIALYSIS; HEMOPHILIA; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INFECTION RATE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; IRAN; THALASSEMIA; HEPACIVIRUS;

HEPACIVIRUS; HEPATITIS C; HUMANS; IRAN;

EID: 84877745977     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Merat S, Malekzadeh R, Rezvan H, Khatibian M. Hepatitis B in Iran. Arch Irn Med. 2000; 3: 192-201.
2. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med. 2009; 12(3): 225-231.
3. Rezvan H, Ahmadi J, Farhadi M, Tardyan S. A preliminary study of prevalence of HCV infection in healthy Iranian blood donors. Vox Sang. 1994; 67(Suppl 2): 149.
4. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010; 14 (suppl 3):113-116.
5. Sarkari B, Eilami O, Khosravani A, Sharifi A, Tabatabaee M, Fararoee M. High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad province, Southwest of Iran. Arch Iran Med. 2012; 15(5): 271-274
6. Hassanshahi G, Arababadi MK, Assar S, Hakimi H, Karimabad MN, Abedinzadeh M, et al. Post-transfusion-transmitted hepatitis C virus infection: a study on thalassemia and hemodialysis patients in south-eastern Iran. Arch Virol. 2011; 156: 1111-1115.
7. Mosavi SA, Mansouri F, Saraei A, Sadeghei A, Merat S. Seroprevalence of hepatitis C in hemophilia patients refering to Iran Hemophilia Society Center in Tehran. Govaresh. 2011; 16: 16-174.
8. Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H. Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon. 2011; 11: 19-22.
9. Zarkesh-Esfahani SH, Kardi MT, Edalati M. Hepatitis C virus genotype frequency in Isfahan province of Iran: a descriptive cross-sectional study. Virol J. 2010; 7: 69.
10. Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis C virus in Iran as reÀected by phylo-genetic analysis of the NS5B region. J Med Virol. 2004; 74: 246-252.
11. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, et al. Safety and efficacy of locally manufactured pegylated in-terferon in hepatitis C patients. Arch Iran Med. 2010; 13(4): 306-312.
12. Mahboobi N, Behnava B, Alavian SM. IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report. Hepat Mon. 2011; 11: 386-388.
13. Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG, et al. The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study. PLoS One. 2011; 6:23830.